Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

AIMS: Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) was the first large clinical trial to include both wild‐type (ATTRwt) and hereditary (ATTRv) patients. A descript...

Descripción completa

Detalles Bibliográficos
Autores principales: Nativi‐Nicolau, Jose, Judge, Daniel P., Hoffman, James E., Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B., Grogan, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497209/
https://www.ncbi.nlm.nih.gov/pubmed/34432383
http://dx.doi.org/10.1002/ehf2.13541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497209/
https://www.ncbi.nlm.nih.gov/pubmed/34432383
http://dx.doi.org/10.1002/ehf2.13541

Ejemplares similares